SCHEMBL3018680

SCHEMBL3018680

COc1cc(Cc2csc(N3CCN(S(=O)(=O)c4cccc(Cl)c4)CC3)n2)cc(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.49
USP2 O75604 1/20 0.49
RECQL P46063 1/20 0.49
HSD17B10 Q99714 1/20 0.49
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.46
TSHR P16473 2/20 0.46
MAPK1 P28482 2/20 0.46
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
GBA1 P04062 3/20 0.42
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.41
HSD11B1 P28845 1/20 0.41
CHRM4 P08173 1/20 0.41
LPAR2 Q9HBW0 1/20 0.40
PTPN11 Q06124 2/20 0.40
PKM P14618 1/20 0.40
PIK3CA P42336 2/20 0.40
MTOR P42345 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015962 0.94 MAPT (0.52) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3016067 0.93 ALDH1A1 (0.51) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3006007 0.91 MAPT (0.45) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3004407 0.90 MAPT (0.51) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3019397 0.89 USP2 (0.45) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3006874 0.89 USP2 (0.49) MAPTUSP2RECQLHSD17B10LMNA
SCHEMBL3006933 0.89 MAPT (0.55) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3012030 0.89 HSD17B10 (0.48) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3016495 0.89 ALDH1A1 (0.48) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3013624 0.88 HSD17B10 (0.50) MAPTUSP2RECQLHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885USP2 1831/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.